Wang Yong, Xu Yiming, Yan Siyuan, Cao Kaixiang, Zeng Xianqiu, Zhou Yaqi, Liu Zhiping, Yang Qiuhua, Pan Yue, Wang Xiaoling, Boison Detlev, Su Yunchao, Jiang Xuejun, Patel Vijay S, Fulton David, Weintraub Neal L, Huo Yuqing
College of Basic Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
Vascular Biology Center, Medical College of Georgia, Augusta University, Augusta, GA, USA.
Cardiovasc Res. 2021 Jan 21;117(2):561-575. doi: 10.1093/cvr/cvaa040.
Adenosine receptors and extracellular adenosine have been demonstrated to modulate vascular smooth muscle cell (VSMC) proliferation and neointima formation. Adenosine kinase (ADK) is a major enzyme regulating intracellular adenosine levels but is function in VSMC remains unclear. Here, we investigated the role of ADK in vascular injury-induced smooth muscle proliferation and delineated the mechanisms underlying its action.
We found that ADK expression was higher in the neointima of injured vessels and in platelet-derived growth factor-treated VSMCs. Genetic and pharmacological inhibition of ADK was enough to attenuate arterial injury-induced neointima formation due to inhibition of VSMC proliferation. Mechanistically, using infinium methylation assays and bisulfite sequencing, we showed that ADK metabolized the intracellular adenosine and potentiated the transmethylation pathway, then induced the aberrant DNA hypermethylation. Pharmacological inhibition of aberrant DNA hypermethylation increased KLF4 expression and suppressed VSMC proliferation as well as the neointima formation. Importantly, in human femoral arteries, we observed increased ADK expression and DNA hypermethylation as well as decreased KLF4 expression in neointimal VSMCs of stenotic vessels suggesting that our findings in mice are relevant for human disease and may hold translational significance.
Our study unravels a novel mechanism by which ADK promotes VSMC proliferation via inducing aberrant DNA hypermethylation, thereby down-regulating KLF4 expression and promoting neointima formation. These findings advance the possibility of targeting ADK as an epigenetic modulator to combat vascular injury.
已证实腺苷受体和细胞外腺苷可调节血管平滑肌细胞(VSMC)增殖和内膜形成。腺苷激酶(ADK)是调节细胞内腺苷水平的主要酶,但其在VSMC中的功能尚不清楚。在此,我们研究了ADK在血管损伤诱导的平滑肌增殖中的作用,并阐明了其作用的潜在机制。
我们发现ADK在受损血管的内膜以及血小板衍生生长因子处理的VSMC中表达较高。对ADK进行基因和药理学抑制足以减轻动脉损伤诱导的内膜形成,这是由于抑制了VSMC增殖。从机制上讲,通过甲基化分析和亚硫酸氢盐测序,我们表明ADK代谢细胞内腺苷并增强转甲基途径,进而诱导异常的DNA高甲基化。对异常DNA高甲基化的药理学抑制增加了KLF4表达,抑制了VSMC增殖以及内膜形成。重要的是,在人股动脉中,我们观察到狭窄血管内膜VSMC中ADK表达增加、DNA高甲基化以及KLF4表达降低,这表明我们在小鼠中的发现与人类疾病相关,可能具有转化意义。
我们的研究揭示了一种新机制,即ADK通过诱导异常的DNA高甲基化来促进VSMC增殖,从而下调KLF4表达并促进内膜形成。这些发现提高了将ADK作为表观遗传调节剂来对抗血管损伤的可能性。